Compare TTRX & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTRX | SKYX |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 149.3M |
| IPO Year | N/A | 2014 |
| Metric | TTRX | SKYX |
|---|---|---|
| Price | $5.99 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.00 | $5.00 |
| AVG Volume (30 Days) | 58.2K | ★ 1.3M |
| Earning Date | 05-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,700,948.00 |
| Revenue This Year | N/A | $25.12 |
| Revenue Next Year | N/A | $24.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.78 |
| 52 Week Low | $2.57 | $0.96 |
| 52 Week High | $6.75 | $3.29 |
| Indicator | TTRX | SKYX |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 41.16 |
| Support Level | $4.70 | N/A |
| Resistance Level | $6.68 | $1.29 |
| Average True Range (ATR) | 0.56 | 0.07 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 53.36 | 15.00 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.